Previous 10 | Next 10 |
home / stock / bhc:cc / bhc:cc news
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations PR Newswire LAVAL, Quebec , Sept. 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the final result...
Bausch Health Companies ( NYSE: BHC ) and Glenmark Pharmaceuticals said their nasal spray Ryaltris was approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated eye symptoms in individuals aged 6 year...
Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada Canada NewsWire - RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms i...
Summary Bausch Health Companies is in the process of spinning off its 90% stake in Bausch & Lomb to shareholders. This stake is worth far more than Bausch Health's current market cap. However, Bausch Health Companies has $19.3 billion in debt, which needs to come down some...
Bausch Health ( TSX:BHC )( NYSE:BHC ) has seen shares climbed by over 30% in the last month alone. At a time when the TSX continues to trade down by 8.55% year to date, Bausch Health stock seems to be on the increase. However, shares are still down by 73% year to date. T...
The TSX today continues to be a pretty scary place to be. Many Canadians were looking forward to a recovery in the near term, but that was short lived. As of writing, shares of the TSX are down 8.3% year to date. But that’s not the case for all companies, including these three gr...
Stocks rebounded from their earlier losses on Monday in a volatile trading session ahead of the Federal Reserve's two-day policy meeting later this week. The Dow Jones Industrials had recovered 27.61 points to break for lunch Monday at 30,850.03. The S&P 500 sank 1.11 points to ...
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations PR Newswire LAVAL, QC , Sept. 14, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the results to date...
Summary Glenview Capital Management’s 13F portfolio value decreased from $4.94B to $4B this quarter. The number of positions decreased from 60 to 55. They increased Cigna, Aptiv plc, and Change Healthcare while dropping Bausch Health, Meritor, and AmerisourceBergen. The...
Bausch Health Companies ( NYSE: BHC ) said its travelers' diarrhea drug Xifaxan's patent protection is till July 24, 2029 and thus a tentatively approved generic version of the drug developed by Norwich Pharmaceuticals' is not expected to hit the U.S. market unti...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC:CC Stock Symbol:
TSXC Market:
Bausch Health Companies Inc. Website:
LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources. The article contains unsubstantiated rumors, including that the Company is considering a bankruptcy o...
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 ...
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business...